InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,098.02
(
0.24%
)
Dow Jones
39,357.01
(
0.00%
)
Brent Oil
81.46
(
-0.18%
)
Bitcoin
58,890.97
(
-0.78%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 115460

Thursday, 02/24/2011 4:47:28 PM

Thursday, February 24, 2011 4:47:28 PM

Post# of 252864
Nice profile piece on Biocon’s founder. Generic insulin could work out well for PFE; the FDA regulates insulin as a small-molecule drug rather than a biologic, and hence generic versions of the insulins from NVO, LLY, and SNY would be automatically substitutable for their branded counterparts.

When PFE announced the Biocon deal in Oct 2010 (#msg-55680051), NVO’s quickly stock fell 10% (#msg-55717310).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up